{"id":4665,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/rituximab-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"rituximab-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/rituximab-txt\/","title":{"rendered":"rituximab.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nMonoclonal antibody: Lymphomas Diffuse large B-cell non-Hodgkin\u2019s lymphoma in combination with other chemotherapy
Rheumatoid arthritis Lupus nephritis (unlicensed)

DOSE IN NORMAL RENAL FUNCTION <\/H3>375 mg\/m 2 weekly for 4 weeksFollicular lymphoma: 375 mg\/m 2 once every 3 months for up to 2 years
Rheumatoid arthritis: two 1 g doses 2 weeks apartLupus nephritis: 375 mg\/m 2 for 1\u20132 doses, two weeks apart

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :144 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : No data<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :76.3 (after 1st infusion)\/\u2013205.8 (after 4th infusion)\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Use with caution
  • 10 to 20 &nbsp &nbsp : Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Use with caution<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Use with caution
  • HDF\/high flux &nbsp :Unlikely to be dialysed. Use with caution
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Use with caution

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • None known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>1st dose: 50 mg\/hour, then increase the rate every 30 minutes by 50 mg\/hour to achieve a maximum rate of 400 mg\/hourFurther doses: 100 mg\/hour, increasing by 100 mg\/hour every 30 minutes to achieve a maximum rate of 400 mg\/hour

    Comments<\/H4>Add to sodium chloride 0.9% or glucose 5% to achieve a concentration of 1\u20134 mg\/mL, and gently invert to prevent foamingUse immediately after dilution. Infusion solution is stable for 12 hours at room temperaturePrepared solution has 24 hrs chemical stability at 2\u20138\u00b0C

    OTHER INFORMATION <\/H4>Always give a premedication of paracetamol and an antihistamine before infusionMean serum half-life increases with dose and repeated dosing (76.3 hours after 1st infusion and 205.8 hours after 4th infusion). Detectable in body for 3\u20136 monthsAlternative regime for vasculitis (anecdotal): 1 g\/m2 on days 1 and 14, repeated at relapse or after 6 monthsPatients with high tumour burden or malignant cells >50 000 mm3 may be at risk of severe cytokine release syndrome which may be associated with acute renal failure \u2013 treat with cautionRituximab has been used to reduce alloreactive antibodies pre-transplant, to treat focal segmental glomerulosclerosis, mixed essential cryoglobulinaemia, SLE, primary systemic vasculitis, PRCA, HUS, and PTLD.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Monoclonal antibody: Lymphomas Diffuse large B-cell non-Hodgkin\u2019s lymphoma<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4665","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4665"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4665\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}